keyword
MENU ▼
Read by QxMD icon Read
search

Parkinson hallucination

keyword
https://www.readbyqxmd.com/read/29709939/a-case-of-fatal-familial-insomnia-initially-developing-parkinsonism-mimicking-dementia-with-lewy-bodies
#1
Takuya Fukuoka, Yoshihiko Nakazato, Masaomi Yamamoto, Akifumi Miyake, Takashi Mitsufuji, Toshimasa Yamamoto
We report a rare case of fatal familial insomnia in a 58-year-old man who initially developed parkinsonism, secondary dementia, and visual hallucinations that were suspected to be due to dementia with Lewy bodies. We evaluated the function of the striatum via dopamine transporter SPECT using 123 I-ioflupane and found marked presynaptic dopamine dysfunction in the bilateral striatum. This is the first reported case in which the initial symptom of fatal familial insomnia was parkinsonism and in which the dopamine transporter function was evaluated by DAT SPECT...
April 27, 2018: Internal Medicine
https://www.readbyqxmd.com/read/29699914/risk-factors-for-non-motor-symptoms-in-parkinson-s-disease
#2
REVIEW
Johan Marinus, Kangdi Zhu, Connie Marras, Dag Aarsland, Jacobus J van Hilten
Non-motor symptoms (NMS) of Parkinson's disease can be predominant as the disease advances, thereby constituting a major source of disease burden for patients and caregivers. However, current understanding of NMS is incomplete, particularly as a result of the absence of standardisation of outcome definitions and the heterogeneity of the risk factors that are assessed. The best data on risk factors for NMS in Parkinson's disease come from longitudinal studies, with the strongest evidence identifying factors for cognitive impairment and dementia, hallucinations, depression, apathy, excessive daytime sleepiness, insomnia, and impulse-control disorders...
April 23, 2018: Lancet Neurology
https://www.readbyqxmd.com/read/29662465/the-length-of-snca-rep1-microsatellite-may-influence-cognitive-evolution-in-parkinson-s-disease
#3
Lucia Corrado, Fabiola De Marchi, Sara Tunesi, Gaia Donata Oggioni, Miryam Carecchio, Luca Magistrelli, Silvana Tesei, Giulio Riboldazzi, Alessio Di Fonzo, Clarissa Locci, Ilaria Trezzi, Roberta Zangaglia, Cristina Cereda, Sandra D'Alfonso, Corrado Magnani, Giacomo P Comi, Giorgio Bono, Claudio Pacchetti, Roberto Cantello, Stefano Goldwurm, Cristoforo Comi
Background: Alpha-synuclein is a constituent of Lewy bodies and mutations of its gene cause familial Parkinson's disease (PD). A previous study showed that a variant of the alpha-synuclein gene ( SNCA ), namely the 263 bp allele of Rep1 was associated with faster motor progression in PD. On the contrary, a recent report failed to detect a detrimental effect of Rep1 263 on both motor and cognitive outcomes in PD. Aim of this study was to evaluate the influence of the Rep1 variants on disease progression in PD patients...
2018: Frontiers in Neurology
https://www.readbyqxmd.com/read/29652961/-severe-leg-edema-associated-with-the-use-of-dopaminergic-drugs-in-parkinson-s-disease-report-of-one-case
#4
Marcelo Miranda C, Lorena Hudson A
The main adverse effects of dopaminergic drugs used in Parkinson's disease are hypotension, somnolence, hallucinations and impulse control disorder. Less common is leg edema. We report on a 68-year-old male receiving levodopa and pramipexole consulting for severe leg edema lasting two years, whose etiology was not ascertained with multiple lab tests. This edema subsided substantially when pramipexole was discontinued and the dose of levodopa was increased to treat motor symptoms.
December 2017: Revista Médica de Chile
https://www.readbyqxmd.com/read/29626263/investigation-of-the-pharmaceutical-care-in-one-elderly-parkinson-s-disease-patient-with-psychotic-symptoms
#5
Chun-Ping Gu, Yue-Liang Xie, Yin-Juan Liao, Cui-Fang Wu, Sheng-Feng Wang, Yu-Lu Zhou, Su-Jie Jia
A 66-year-old male patient with a 10-year course of Parkinson's disease (PD) was admitted for hallucination lasting a half a month. After treatment with levodopa/carbidopa, selegiline, and piribedil, the patient's motor symptoms were improved while no significant effects were observed on psychotic symptoms. A clinical pharmacist analyzed the pharmacologic and pharmacokinetic characteristics of selegiline and piribedil, summarized the scheme of PD with psychotic symptoms in the literature, and discovered that selegiline might potentiate psychotic side effects of piribedil, while the use of levodopa/carbidopa cannot be ruled out either...
April 6, 2018: Drug Safety—Case Reports
https://www.readbyqxmd.com/read/29618627/baseline-symptoms-and-basal-forebrain-volume-predict-future-psychosis-in-early-parkinson-disease
#6
Matthew J Barrett, Jamie C Blair, Scott A Sperling, Mark E Smolkin, T Jason Druzgal
OBJECTIVE: Determining baseline predictors of future psychosis in Parkinson disease (PD) may identify those at risk for more rapidly progressive disease, i.e., a more malignant PD subtype. METHODS: This cohort study evaluated 423 patients with newly diagnosed PD collected as part of the Parkinson's Progression Markers Initiative. Psychotic symptoms were assessed with the Movement Disorders Society-Unified Parkinson Disease Rating Scale item 1.2, which assesses hallucinations and psychosis over the past week...
May 1, 2018: Neurology
https://www.readbyqxmd.com/read/29593637/structural-and-functional-brain-patterns-of-non-motor-syndromes-in-parkinson-s-disease
#7
REVIEW
Tino Prell
Parkinson's disease (PD) is a common, progressive and multisystem neurodegenerative disorder characterized by motor and non-motor symptoms. Advanced magnetic resonance imaging, positron emission tomography, and functional magnetic resonance imaging can render the view toward understanding the neural basis of these non-motor syndromes, as they help to understand the underlying pathophysiological abnormalities. This review provides an up-to-date description of structural and functional brain alterations in patients with PD with cognitive deficits, visual hallucinations, fatigue, impulsive behavior disorders, sleep disorders, and pain...
2018: Frontiers in Neurology
https://www.readbyqxmd.com/read/29570843/molecular-changes-in-the-absence-of-severe-pathology-in-the-pulvinar-in-dementia-with-lewy-bodies
#8
Daniel Erskine, Jinhui Ding, Alan J Thomas, Alice Kaganovich, Ahmad A Khundakar, Peter S Hanson, John-Paul Taylor, Ian G McKeith, Johannes Attems, Mark R Cookson, Christopher M Morris
BACKGROUND: Dementia with Lewy bodies is characterized by transient clinical features, including fluctuating cognition and visual hallucinations, implicating dysfunction of cerebral hub regions, such as the pulvinar nuclei of the thalamus. However, the pulvinar is typically only mildly affected by Lewy body pathology in dementia with Lewy bodies, suggesting additional factors may account for its proposed dysfunction. METHODS: We conducted a comprehensive analysis of postmortem pulvinar tissue using whole-transcriptome RNA sequencing, protein expression analysis, and histological evaluation...
March 23, 2018: Movement Disorders: Official Journal of the Movement Disorder Society
https://www.readbyqxmd.com/read/29569570/behavioral-and-psychological-symptoms-in-lewy-body-disease-a-review
#9
Lucie Jurek, Mathieu Herrmann, Mathilde Bonze, Sophie Brunet, Catherine Padovan, Jean-Michel Dorey
Dementia with Lewy bodies (DLB) is a common neurodegenerative disease, second in terms of prevalence after Alzheimer's disease (AD). DLB may be suspected according to three core features which are cognitive and motor fluctuations, early visual hallucinations and parkinsonism; and more recently, according to the new criteria, REM sleep behavior disorder (RBD). Behavorial and psychological symptoms associated with DLB are more frequent, more severe and appear earlier than those found in other neurodegenerative diseases...
March 1, 2018: Gériatrie et Psychologie Neuropsychiatrie du Vieillissement
https://www.readbyqxmd.com/read/29569562/a-new-tool-to-adapt-the-treatment-of-parkinson-s-disease-patients-in-nursing-homes
#10
Christian Geny, Claudia Verna, Alexia Arifi, Ernestine Ferreira, Choukri Boubakri, Hubert Blain
Parkinson's disease (PD) is a common condition in nursing home (NH) residents. The primary treatment for Parkinson's disease is levodopa therapy to relieve motor symptoms and maximize physical function. Non-motor symptoms are highly prevalent in NH residents with Parkinson's disease and dramatically decrease quality of life. Choices in drug treatment need to take into account the complex interactions between aging, comorbidity and non-motor symptoms. Optimal management requires expertise and cooperative effort from prescribing neurologists and nursing home health professionals...
March 1, 2018: Gériatrie et Psychologie Neuropsychiatrie du Vieillissement
https://www.readbyqxmd.com/read/29564954/the-role-of-extended-release-amantadine-for-the-treatment-of-dyskinesia-in-parkinson-s-disease-patients
#11
Elkurd T Mazen, Laxman B Bahroo, Rajesh Pahwa
Levodopa is the most efficacious treatment for Parkinson's disease (PD). Long-term treatment with levodopa is limited due to dyskinesia. Dyskinesia in PD can be socially and functionally disabling. Extended-release amantadine (amantadine ER) is the first approved medication for the treatment of dyskinesia. When it is given at bedtime, it reaches plasma concentration approximately twice the level achieved by amantadine immediate release. Amantadine ER reduces the severity and duration of dyskinesia during the day, reduces OFF time and increases ON time without troublesome dyskinesia...
March 22, 2018: Neurodegenerative Disease Management
https://www.readbyqxmd.com/read/29560902/visual-hallucinations-are-characterized-by-impaired-sensory-evidence-accumulation-insights-from-hierarchical-drift-diffusion-modeling-in-parkinson-s-disease
#12
Claire O'Callaghan, Julie M Hall, Alessandro Tomassini, Alana J Muller, Ishan C Walpola, Ahmed A Moustafa, James M Shine, Simon J G Lewis
BACKGROUND: Models of hallucinations emphasize imbalance between sensory input and top-down influences over perception, as false perceptual inference can arise when top-down predictions are afforded too much precision (certainty) relative to sensory evidence. Visual hallucinations in Parkinson's disease (PD) are associated with lower-level visual and attentional impairments, accompanied by overactivity in higher-order association brain networks. PD therefore provides an attractive framework to explore contributions of bottom-up versus top-down disturbances in hallucinations...
November 2017: Biological Psychiatry: Cognitive Neuroscience and Neuroimaging
https://www.readbyqxmd.com/read/29541542/predictors-of-freezing-of-gait-in-chinese-patients-with-parkinson-s-disease
#13
Ruwei Ou, Qianqian Wei, Bei Cao, Wei Song, Yanbing Hou, Hui Liu, Xiaoqin Yuan, Bi Zhao, Ying Wu, Huifang Shang
Objective: To explore the clinical predictors of freezing of gait (FOG) in Chinese patients with Parkinson's disease (PD). Methods: This study included 225 patients with PD who completed a three-year follow-up visit. The end-point was the presence of FOG (freezers), which was assessed during the follow-up visit. Group comparisons were conducted, followed by a further forward binary logistic regression analysis. Results: Eighty-five patients with PD (38%) had developed FOG at the end of study...
March 2018: Brain and Behavior
https://www.readbyqxmd.com/read/29532440/pooled-analyses-of-phase-iii-studies-of-ads-5102-amantadine-extended-release-capsules-for-dyskinesia-in-parkinson-s-disease
#14
Lawrence W Elmer, Jorge L Juncos, Carlos Singer, Daniel D Truong, Susan R Criswell, Sotirios Parashos, Larissa Felt, Reed Johnson, Rajiv Patni
BACKGROUND: Although levodopa is considered the most effective pharmacotherapy for motor symptoms of Parkinson's disease (PD), chronic use is associated with motor complications, including fluctuating response and unpredictable, involuntary movements called dyskinesia. ADS-5102 (amantadine) extended-release (ER) capsules (GOCOVRITM ) is a recent US FDA-approved treatment for dyskinesia in PD patients. ADS-5102 is a high-dose, ER formulation of amantadine, administered orally once daily at bedtime, that achieves high plasma drug concentrations throughout the day...
April 2018: CNS Drugs
https://www.readbyqxmd.com/read/29528896/toward-personalized-treatment-of-hallucinations
#15
Iris E Sommer, Hidde Kleijer, Kenneth Hugdahl
PURPOSE OF REVIEW: Hallucinations are common and often stressful experiences, occurring in all sensory modalities. They frequently complicate many disorders or situations, such as Parkinson's disease, schizophrenia, hearing or vision loss, intoxications and delirium. Although psychoeducation, coping techniques and psychotherapy may be broadly applicable, they do not address a specific underlying brain mechanism. Pharmacotherapy may effectively alleviate hallucinations if the corresponding mechanism is present, whereas in its absence, may only cause harmful side effects...
May 2018: Current Opinion in Psychiatry
https://www.readbyqxmd.com/read/29525296/further-evidence-for-a-distinctive-atypical-degenerative-parkinsonism-in-the-caribbean-a-new-cluster-in-the-french-west-indian-island-of-martinique
#16
Annie Lannuzel, Régine Edragas, Angéla Lackmy, Benoit Tressières, Véronique Pelonde, Mireille Edimo Nana Kaptué, Sylvie Mécharles, Alexis Demas, Billy François, Eavan McGovern, Marie Vidailhet, Bertrand Gaymard, Emmanuel Roze
BACKGROUND: A high prevalence of an atypical levodopa-resistant parkinsonism has been reported in the Caribbean island of Guadeloupe. These seminal observations have not been replicated or extended to neighbouring populations who share genetic and environmental characteristics. METHODS: To further characterise this atypical parkinsonism we prospectively investigated 305 consecutive patients with neurodegenerative parkinsonism in a community-based population from Guadeloupe and Martinique, a neighbouring French Caribbean island where the population has similar environmental and genetic backgrounds...
May 15, 2018: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/29511826/efficacy-and-safety-of-amantadine-for-the-treatment-of-l-dopa-induced-dyskinesia
#17
REVIEW
Santiago Perez-Lloret, Olivier Rascol
L-DOPA induced dyskinesias (LIDs) may affect up to 40% of Parkinson's disease (PD) and impact negatively health-related quality of life. Amantadine has demonstrated significant antidyskinetic effects in animal PD models and in randomized double-blind placebo-controlled trials (RCTs) in patients with PD. These effects are thought to be related to the blockade of NMDA receptors modulating cortico-striatal glutamatergic-dopaminergic interactions involved in the genesis of LIDs. There are three pharmaceutical forms of amantadine currently available in the market: an oral immediate-release (IR) formulation, which is widely available; an extended-release (ER) formulation (ADS-5102) which has been recently developed and approved by the FDA; and an intravenous infusion (IV) solution, which is not commonly used in clinical practice...
March 7, 2018: Journal of Neural Transmission
https://www.readbyqxmd.com/read/29510692/are-dementia-with-lewy-bodies-and-parkinson-s-disease-dementia-the-same-disease
#18
Kurt A Jellinger, Amos D Korczyn
BACKGROUND: Dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD), which share many clinical, neurochemical, and morphological features, have been incorporated into DSM-5 as two separate entities of major neurocognitive disorders with Lewy bodies. Despite clinical overlap, their diagnosis is based on an arbitrary distinction concerning the time of onset of motor and cognitive symptoms, namely as early cognitive impairment in DLB and later onset following that of motor symptoms in PDD...
March 6, 2018: BMC Medicine
https://www.readbyqxmd.com/read/29502255/pathophysiology-of-dyskinesia-and-behavioral-disorders-in-non-human-primates-the-role-of-serotonergic-fibers
#19
REVIEW
Véronique Sgambato, Léon Tremblay
The MPTP monkey model of Parkinson's disease (PD) has allowed huge advances regarding the understanding of the pathological mechanisms of PD and L-DOPA-induced adverse effects. Among the main findings were the imbalance between the efferent striatal pathways in opposite directions between the hypokinetic and hyperkinetic states of PD. In both normal and parkinsonian monkeys, the combination of behavioral and anatomical studies has allowed the deciphering of the cortico-basal ganglia circuits involved in both movement and behavioral disorders...
March 3, 2018: Journal of Neural Transmission
https://www.readbyqxmd.com/read/29494265/pharmacological-interventions-for-psychosis-in-parkinson-s-disease-patients
#20
Joseph H Friedman
Psychosis is a common problem for people treated for Parkinson's disease. The syndrome is quite stereotypic, with hallucinations being the most common, followed by delusions. While the hallucinations are usually not very bothersome, the delusions are typically paranoid in nature. Treatment is often, but not always, required. Areas covered: This article reviews the therapeutic approaches of this syndrome focusing on drug treatments used once contributory factors have been removed. This includes a review of the evidence supporting the use of clozapine and, most recently, pimavanserin, the first drug with antipsychotic efficacy that has no effect on dopamine...
April 2018: Expert Opinion on Pharmacotherapy
keyword
keyword
48244
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"